You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Neuroplastic Effects of Transcranial Direct Current Stimulation on Painful Symptoms Reduction in Chronic Hepatitis C: A Phase II Randomized, Double Blind, Sham Controlled Trial
|
|---|---|
| Published in |
Frontiers in Neuroscience, January 2016
|
| DOI | 10.3389/fnins.2015.00498 |
| Pubmed ID | |
| Authors |
Aline P. Brietzke, Joanna R. Rozisky, Jairo A. Dussan-Sarria, Alicia Deitos, Gabriela Laste, Priscila F. T. Hoppe, Suzana Muller, Iraci L. S. Torres, Mário R. Alvares-da-Silva, Rivadavio F. B. de Amorim, Felipe Fregni, Wolnei Caumo |
| Abstract |
Pegylated Interferon Alpha (Peg-IFN) in combination with other drugs is the standard treatment for chronic hepatitis C infection (HCV) and is related to severe painful symptoms. The aim of this study was access the efficacy of transcranial direct current stimulation (tDCS) in controlling the painful symptoms related to Peg-IFN side effects. In this phase II double-blind trial, twenty eight (n = 28) HCV subjects were randomized to receive either 5 consecutive days of active tDCS (n = 14) or sham (n = 14) during 5 consecutive days with anodal stimulation over the primary motor cortex region using 2 mA for 20 min. The primary outcomes were visual analogue scale (VAS) pain and brain-derived neurotrophic factor (BDNF) serum levels. Secondary outcomes were the pressure-pain threshold (PPT), the Brazilian Profile of Chronic Pain: Screen (B-PCP:S), and drug analgesics use. tDCS reduced the VAS scores (P < 0.003), with a mean pain drop of 56% (p < 0.001). Furthermore, tDCS was able to enhance BDNF levels (p < 0.01). The mean increase was 37.48% in the active group. Finally, tDCS raised PPT (p < 0.001) and reduced the B-PCP:S scores and analgesic use (p < 0.05). Five sessions of tDCS were effective in reducing the painful symptoms in HCV patients undergoing Peg-IFN treatment. These findings support the efficacy of tDCS as a promising therapeutic tool to improve the tolerance of the side effects related to the use of Peg-IFN. Future larger studies (phase III and IV trials) are needed to confirm the clinical use of the therapeutic effects of tDCS in such condition. Brazilian Human Health Regulator for Research with the approval number CAAE 07802012.0.0000.5327. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| Canada | 1 | 20% |
| Switzerland | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 2% |
| Italy | 1 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 113 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 19 | 16% |
| Student > Bachelor | 17 | 15% |
| Student > Ph. D. Student | 12 | 10% |
| Researcher | 11 | 9% |
| Student > Doctoral Student | 10 | 9% |
| Other | 22 | 19% |
| Unknown | 26 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 24% |
| Neuroscience | 15 | 13% |
| Nursing and Health Professions | 13 | 11% |
| Psychology | 10 | 9% |
| Unspecified | 5 | 4% |
| Other | 13 | 11% |
| Unknown | 33 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2016.
All research outputs
#14,255,756
of 25,373,627 outputs
Outputs from Frontiers in Neuroscience
#5,552
of 11,538 outputs
Outputs of similar age
#187,729
of 400,967 outputs
Outputs of similar age from Frontiers in Neuroscience
#71
of 143 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,538 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,967 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 143 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.